What D76 covers · when clinicians use it
ICD-10 code D76 identifies Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue in the U.S. ICD-10-CM clinical and billing record set. It sits within the Blood & Blood-forming Organs chapter (D50–D89), the section that groups related diagnoses so providers, payers, and public-health agencies report them consistently. Clinicians and medical coders apply D76 when an encounter's findings match the Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue description, attaching it to the patient record so downstream insurance claims, payer audits, quality reporting, and epidemiological surveillance all reference the same standardized diagnosis. The ICD-10-CM is maintained by the Centers for Medicare & Medicaid Services and the CDC's National Center for Health Statistics, with an updated official code set released each U.S. fiscal year — always verify D76 against the current CMS/CDC release and your payer's documentation guidance before final use. This page summarizes documentation context for D76 and is a coding reference, not clinical, diagnostic, or billing advice.
D76 refers to Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue, a category of hematologic disorders affecting white blood cells, spleen function, or oxygen-carrying capacity. These conditions can result from genetic mutations, infections, immune dysfunction, or secondary effects of other diseases and treatments like chemotherapy.
Symptoms
- Increased infections – Particularly in neutropenia or WBC dysfunction
- Fever – Often the first sign in immunocompromised individuals
- Enlarged spleen – Seen in many splenic and lymphoreticular disorders
- Blue-tinged skin or lips – A sign of methemoglobinemia
- Fatigue – Common with blood oxygenation issues or systemic inflammation
- Easy bruising or bleeding – If spleen involvement reduces platelet counts
- Pallor or poor circulation – Seen in severe systemic blood disorders
Diagnosis
Diagnosis of Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue involves a combination of CBC with differential, peripheral blood smear, bone marrow biopsy, spleen ultrasound, methemoglobin levels, and sometimes genetic or immunologic testing. The cause and severity guide treatment and monitoring.
ICD10 Code Usage
ICD10 code D76 is used across internal medicine, hematology, oncology, and infectious disease. It supports accurate coding for immunodeficiencies, white cell abnormalities, spleen diseases, and systemic hematologic conditions linked to other diagnoses.
Related Codes
- D70 – Neutropenia
- D71 – Functional disorders of polymorphonuclear neutrophils
- D72 – Other disorders of white blood cells
- D73 – Diseases of spleen
- D74 – Methemoglobinemia
- D75 – Other and unspecified diseases of blood and blood-forming organs
- D77 – Other disorders of blood and blood-forming organs in diseases classified elsewhere
FAQs
Q1: What is ICD10 code D76?
A: This code documents Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue, a type of white blood cell or spleen disorder in clinical records.
Q2: What causes these conditions?
A: Causes include congenital immune defects, chemotherapy, infections, inflammatory diseases, or toxins.
Q3: Are these conditions serious?
A: Yes, they can predispose to life-threatening infections or systemic complications if unmanaged.
Q4: How are they treated?
A: Antibiotics, immunoglobulin therapy, granulocyte colony-stimulating factors (G-CSF), oxygen therapy, or splenectomy depending on the condition.
Q5: Who manages these disorders?
A: Hematologists, immunologists, infectious disease experts, and sometimes oncologists or surgeons.
Conclusion
ICD10 code D76 plays a key role in diagnosing and tracking Other specified diseases with participation of lymphoreticular and reticulohistiocytic tissue. Accurate classification ensures appropriate evaluation, risk monitoring, and individualized treatment plans for these complex and often immunologically significant disorders.